



ABOLOGIX is admitted to Fondation Ecllosion, the Geneva life sciences incubator

- **Abologix has been selected to participate in the incubation program sponsored by *Fondation Ecllosion***
- **As part of this program Abologix will receive business, scientific and financial support from *Fondation Ecllosion***

Geneva, Switzerland, September 5, 2018.

Abologix has been selected to enter *Fondation Ecllosion*, the Geneva Life Sciences incubator supported by the *Republique et canton de Genève*. Under the program Abologix will receive invaluable business, scientific and financial support.

“We are honoured and grateful to have been selected to participate in this incubation program. This will allow the company to access critical resources required for its growth. We hope to make a lasting contribution to the growth of the biotechnology ecosystem in the city of Geneva”. said Ignacio Faus, co-founder and Chairman of the Board of Abologix.

About Abologix

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule **JAM-C** and the extracellular matrix-related protein **Olfactomedin-like protein 3 (Olfml3)** for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Geneva and the Hôpitaux Universitaires de Genève.

Contact Information

Ignacio Faus, Chairman of the Board
Abologix Sàrl
ignaciofaus@abologix.com